Catabasis Pharmaceuticals Stock Forecast, Price & News

Catabasis Pharmaceuticals' stock was trading at $4.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CATB stock has decreased by 66.2% and is now trading at $1.50.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Catabasis Pharmaceuticals.

Wall Street analysts have given Catabasis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catabasis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Catabasis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Catabasis Pharmaceuticals.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) posted its quarterly earnings results on Tuesday, November, 17th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.05.
View Catabasis Pharmaceuticals' earnings history.

Shares of Catabasis Pharmaceuticals reverse split on Monday, December 31st 2018. The 1-10 reverse split was announced on Monday, December 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 28th 2018. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

3 analysts have issued 1-year price targets for Catabasis Pharmaceuticals' shares. Their forecasts range from $15.00 to $60.00. On average, they anticipate Catabasis Pharmaceuticals' share price to reach $33.00 in the next year. This suggests a possible upside of 2,100.0% from the stock's current price.
View analysts' price targets for Catabasis Pharmaceuticals.

Catabasis Pharmaceuticals saw a decrease in short interest in the month of October. As of October 30th, there was short interest totaling 644,100 shares, a decrease of 18.1% from the October 15th total of 786,800 shares. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is presently 0.6 days.
View Catabasis Pharmaceuticals' Short Interest.

Some companies that are related to Catabasis Pharmaceuticals include Xynomic Pharmaceuticals (XYNO), Orgenesis (ORGS), Cocrystal Pharma (COCP), Infinity Pharmaceuticals (INFI), Aytu BioScience (AYTU), Enlivex Therapeutics (ENLV), Antibe Therapeutics (ATBPF), Immunome (IMNM), Cyclerion Therapeutics (CYCN), Corvus Pharmaceuticals (CRVS), Sio Gene Therapies (SIOX), PhaseBio Pharmaceuticals (PHAS), Chembio Diagnostics (CEMI), Lipocine (LPCN) and Oncolytics Biotech (ONCY).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catabasis Pharmaceuticals investors own include G-III Apparel Group (GIII), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), Aldeyra Therapeutics (ALDX), Aurinia Pharmaceuticals (AUPH), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

(CATB) raised $60 million in an IPO on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

Catabasis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (1.27%), Wells Fargo & Company MN (0.68%), WINTON GROUP Ltd (0.23%), Schonfeld Strategic Advisors LLC (0.07%), Schonfeld Strategic Advisors LLC (0.07%) and JPMorgan Chase & Co. (0.07%).
View institutional ownership trends for Catabasis Pharmaceuticals.

CATB stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd.
View insider buying and selling activity for Catabasis Pharmaceuticals.

CATB stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, State Street Corp, Schonfeld Strategic Advisors LLC, Schonfeld Strategic Advisors LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Catabasis Pharmaceuticals.

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CATB stock can currently be purchased for approximately $1.50.

Catabasis Pharmaceuticals has a market capitalization of $30.13 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-26,290,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. Catabasis Pharmaceuticals employs 27 workers across the globe.

The official website for Catabasis Pharmaceuticals is www.catabasis.com.

Catabasis Pharmaceuticals' mailing address is 100 High StreetFloor 28, Boston MA, 02110. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]